What's new

Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 8, Status: Authorised

Apr 10, 2025 - 15:28
 0
Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 8, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Darzalex, daratumumab,...

Next Article

Welcome to the Deepal SO7 — 1st Drive Review

Related Posts

Human medicines European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories), mercaptopurine, Date of authorisation: 09/03/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Vaborem, meropenem trihydrate,vaborbactam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0530/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 13, 2025  0

Summary of opinion: Tremfya, 27/03/2025 Positive

Summary of opinion: Tremfya, 27/03/2025 Positive

Mar 28, 2025  0